

Paracetamol (acetaminophen)



Essential medicine status ✓

Section: [5. Medicines for neurological disorders](#) > [5.1. Medicines for central nervous system disorders](#) > [5.1.5. Medicines for headache disorders](#) > [5.1.5.1. Medicines for acute migraine attacks](#)

EMLc

ATC codes: [N02BE01](#)

Indication	Migraine ICD11 code: 8A80.Z
INN	Paracetamol
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Additional notes	*The presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided
Formulations	Oral > Liquid: 125 mg per 5 mL (EMLc) ; 120 mg per 5 mL (EMLc) ; 250 mg per 5 mL (EMLc) Local > Rectal > Suppository: 250 mg (EMLc) Oral > Solid > dispersible tablet: 100 mg (EMLc) ; 250 mg (EMLc) Oral > Solid > tablet: 250 mg ; 325 mg ; 500 mg
EML status history	First added in 1987 (TRS 770) Changed in 2007 (TRS 950) Changed in 2017 (TRS 1006) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents. ↗
Wikipedia	Paracetamol (acetaminophen) ↗
DrugBank	Paracetamol (Acetaminophen) ↗

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of the 100 mg tablet formulation from the EML and EMLc - strengths of paracetamol tablets should be specified rather than given in a range - the addition of a 250 mg strength suppository formulation to the EMLc - the addition of paracetamol dispersible tablets (100 mg and 250 mg) to the EMLc - the addition of 250 mg/5mL strength oral liquid formulation to the EMLc - the addition of a note stating "the presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided"

